<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03660553</url>
  </required_header>
  <id_info>
    <org_study_id>20180541</org_study_id>
    <nct_id>NCT03660553</nct_id>
  </id_info>
  <brief_title>Simplified Insulin Regimen for the Elderly</brief_title>
  <official_title>Effect of Simplified Insulin Regimen on Glycemic Control and Quality of Life in an Elderly Population With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Basal-bolus insulin therapy, which includes one injection of long acting insulin and three
      injections of short acting insulin is the most commonly used insulin treatment. However, many
      older patients find the basal-bolus insulin regimen hard to manage because it involves 4
      injections and 4 blood glucose tests each day. It is possible that a simplified treatment
      that involves one injection of long acting insulin daily and two blood glucose tests daily
      might be equally effective. This simplified regimen, if effective, would be easier to use and
      might result in less errors. Therefore, the investigators want to conduct this study to
      compare using a single daily injection of basal insulin with the usual basal-bolus insulin
      regimen in elderly patients (age &gt;65 years) with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin A1c (HbA1c)</measure>
    <time_frame>6 months</time_frame>
    <description>The mean HbA1c in the BI group will be compared to the mean HbA1c in the MSI group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average blood glucose levels</measure>
    <time_frame>6 months</time_frame>
    <description>Average of home monitored blood glucose levels will be compared between the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of any hypoglycemia</measure>
    <time_frame>6 months</time_frame>
    <description>Defined as any reported blood glucose (BG) &lt;70 mg/dl will be compared between the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe hypoglycemia</measure>
    <time_frame>6 months</time_frame>
    <description>Any BG &lt;54 mg/dl or patient requiring assistance to recover from hypoglycemia will be compared between 2 groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Multiple Subcutaneous Injection (MSI)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MSI group will receive four insulin injections per day that will include a long acting and a short acting insulin. Short acting insulin will be either insulin aspart or insulin lispro.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Basal Insulin (BI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI group will receive only one injection of insulin glargine in the morning.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <description>0.40 units/kg body weight</description>
    <arm_group_label>Basal Insulin (BI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <description>0.20 units/kg body weight</description>
    <arm_group_label>Multiple Subcutaneous Injection (MSI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Aspart</intervention_name>
    <description>0.20 units/kg body weight</description>
    <arm_group_label>Multiple Subcutaneous Injection (MSI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Lispro</intervention_name>
    <description>0.20 units/kg body weight</description>
    <arm_group_label>Multiple Subcutaneous Injection (MSI)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Age &gt;65 years

        Exclusion Criteria:

          -  Unable to provide informed consent

          -  Enrollment in another research study

          -  History of hypoglycemia unawareness

          -  Pregnant women

          -  Prisoners
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajesh Garg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rajesh Garg, MD</last_name>
    <phone>3056890257</phone>
    <email>rgarg@miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajesh Garg, MD</last_name>
      <phone>305-689-0257</phone>
      <email>rgarg@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Rajesh Garg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniela Pirela, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>September 4, 2018</study_first_submitted>
  <study_first_submitted_qc>September 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2018</study_first_posted>
  <last_update_submitted>December 6, 2019</last_update_submitted>
  <last_update_submitted_qc>December 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Rajesh Garg</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Elderly</keyword>
  <keyword>Insulin treatment</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

